Loading
Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article
Frontiers in Oncology · August 13, 2026
Encouraging direction, but not yet definitive.
This single-center retrospective comparison of ICI+chemotherapy versus bevacizumab+chemotherapy in driver gene-negative advanced non-squamous NSCLC shows superior median PFS (14.330 vs 9.60 months) and ORR (41.77% vs 26.09%) favoring ICIs, with acceptable but distinct toxicity profiles. The findings are promising but limited by retrospective design, unbalanced allocation, and lack of adjustment for potential confounders; prospective validation is needed.
Single-center retrospective cohort study. Patients with driver gene-negative advanced non-squamous NSCLC treated as first-line at a single hospital center. No explicit mention of additional eligibility criteria, performance status requirements, or exclusion criteria beyond driver gene-negative status.. Intervention: Immune checkpoint inhibitors combined with chemotherapy (4–6 cycles followed by maintenance therapy).. Compared with: Bevacizumab combined with chemotherapy (4–6 cycles followed by maintenance therapy).. n = 194. Single center; location not specified..
Median PFS: 14.330 months (ICIs+chemotherapy) vs 9.60 months (bevacizumab+chemotherapy), P = 0.014 ORR: 41.77% (ICIs+chemotherapy) vs 26.09% (bevacizumab+chemotherapy), P = 0.022 DCR: 84.81% (ICIs+chemotherapy) vs 79.13% (bevacizumab+chemotherapy), P = 0.317 (not significant)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
For clinicians treating driver gene-negative advanced non-squamous NSCLC without targetable mutations, these findings suggest ICI+chemotherapy may offer superior progression-free survival and response rates compared to bevacizumab+chemotherapy, particularly in PD-L1 high-expressing tumors. However, the retrospective design and unbalanced allocation warrant caution; prospective trial data should be awaited before changing practice, and subgroup findings suggesting some populations benefit more from bevacizumab warrant further investigation.
Single-center retrospective study showing superior PFS and ORR for ICI+chemotherapy versus bevacizumab+chemotherapy in driver gene-negative NSCLC, but limited by retrospective design, unbalanced group sizes, and lack of adjustment for confounders.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians treating driver gene-negative advanced non-squamous NSCLC without targetable mutations, these findings suggest ICI+chemotherapy may offer superior progression-free survival and response rates compared to bevacizumab+chemotherapy, particularly in PD-L1 high-expressing tumors. However, the retrospective design and unbalanced allocation warrant caution; prospective trial data should be awaited before changing practice, and subgroup findings suggesting some populations benefit more from bevacizumab warrant further investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Purpose To compare the efficacy and safety of immune checkpoint inhibitors (ICIs) versus bevacizumab (both combined with chemotherapy) for first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC). Methods This single-center retrospective study enrolled 194 patients with driver gene-negative advanced non-squamous NSCLC treated at our hospital from May 1, 2019, to May 1, 2025: 79 received ICIs plus chemotherapy, and 115 received bevacizumab plus chemotherapy. Both groups received 4–6 cycles of combination therapy followed by maintenance therapy until disease progression or the end of the study. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Results Short-term efficacy: ORR was significantly higher in the ICIs plus chemotherapy group than in the bevacizumab plus chemotherapy group (41.77% vs 26.09%, P = 0.022), while DCR showed no statistically significant difference between groups (84.81% vs 79.13%, P = 0.317). Survival benefit: Median PFS was 14.330 months in the ICIs plus chemotherapy group, which was superior to 9.60 months in the bevacizumab plus chemotherapy group ( P = 0.014). Safety: The ICIs plus chemotherapy group had a higher incidence of thyroid dysfunction (8.86% vs 0%, P = 0.002), immune-related pneumonitis (3.80% vs 0%, P = 0.066) and immune-related hepatitis (5.06% vs 0%, P = 0.026); the bevacizumab plus chemotherapy group had a higher incidence of proteinuria (7.83% vs 0%, P = 0.012) and hypertension (6.96% vs 0%, P = 0.022). Other AEs were comparable between the two groups. Subgroup analysis: Higher disease progression risk was observed in the bevacizumab plus chemotherapy group for patients with PD-L1 high expression (HR = 3.731, P = 0.039), indicating this population benefits more from ICIs plus chemotherapy. Higher progression risk was seen in the ICIs plus chemotherapy group for males (HR = 2.410, P = 0.015), ever-smokers (HR = 2.215, P = 0.047), patients with ECOG score 0-1 (HR = 1.762, P = 0.032) and patients without bone metastasis (HR = 2.112, P = 0.036), suggesting these subgroups are more likely to benefit from bevacizumab plus chemotherapy. Conclusions For patients with driver gene-negative advanced non-squamous NSCLC, ICIs combined with chemotherapy are superior to bevacizumab combined with chemotherapy in terms of short-term efficacy and progression-free survival, with manageable but distinct adverse event profiles.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.